Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

BACKGROUND: Published literature suggests that early treatment with natalizumab (“escalation strategy”) is more effective than switch within the same class of immunomodulators (interferons/glatiramer acetate, “switching strategy”) in relapsing-remitting multiple sclerosis (RRMS) patients who failed...

Descripción completa

Detalles Bibliográficos
Autores principales: Furneri, Gianluca, Santoni, Laura, Ricella, Chiara, Prosperini, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599237/
https://www.ncbi.nlm.nih.gov/pubmed/31253138
http://dx.doi.org/10.1186/s12913-019-4264-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599237/
https://www.ncbi.nlm.nih.gov/pubmed/31253138
http://dx.doi.org/10.1186/s12913-019-4264-1

Ejemplares similares